Boston, MA, United States
Boston, MA, United States

Aberdeen Group Inc. is a provider of fact-based business intelligence research founded in 1988, trying to "understand the implications and results of process innovation, methodology advancements, technology deployments, and business re-engineering". Wikipedia.

Time filter

Source Type

News Article | April 17, 2017

Izenda and Aberdeen Group announced today that they will host an interactive webinar, “Tailor-Made Insight: Enriching Applications with Embedded Analytical Horsepower,” on Thursday, April 27 from 2-3 p.m. (ET). Speakers will include Chuck Demaree, CTO of Access, and Michael Lock, vice president of Aberdeen Research and an acknowledged embedded business intelligence (BI) expert. Software product teams need to create powerful business tools that end users find easy to use. Embedded BI is fast becoming mission critical for today’s leading software providers. In fact, according to Aberdeen Group, embedded analytics leaders are three and half times more likely to see an increase in revenue greater than 20 percent. Demaree and Lock will lead the webinar sharing their perspective on the value embedded BI brings to application developers and ultimately end users. They will review: Izenda offers an embedded self-service business intelligence (BI) and analytics platform purpose built for software companies, solutions providers and their customers. Izenda integrates seamlessly in applications to deliver BI and analytics directly to the people who need it most – application end users who want to easily analyze, visualize, and share valuable data and insights in real time. Based in Atlanta, Ga. and founded in 2007, Izenda is used by more than 10,000 organizations on a daily basis.

Warris A.,Aberdeen Group
Journal of Infection | Year: 2015

Azole-resistance in Aspergillus fumigatus is emerging and is becoming an increasing problem in the management of aspergillosis. Two types of development of resistance have been described; resistance acquired during azole treatment in an individual patient and through environmental exposure to fungicides. The main molecular mechanism of azole resistance in A. fumigatus is explained by mutations in the cyp51A-gene. The environmental route of resistance development is particularly worrying and may affect all patients whether azole exposed or naïve, and whether suffering from acute or chronic aspergillosis. No management guidelines to assist clinicians confronted with azole-resistant aspergillosis are available and pre-clinical and clinical evidence supporting treatment choices is scarce. © 2015 The British Infection Association.

The microbial communities found in the mammalian large intestine and rumen efficiently degrade many recalcitrant substrates that are resistant to the host's digestive enzymes. These communities are known from molecular profiling to be highly diverse at the species and strain level, but it may be that only certain specialized organisms ("keystone species") have the ability to initiate degradation of such substrates, thus releasing energy on which the rest of the community depends. We have recently reported that Ruminococcus bromii has a superior ability to degrade certain forms of particulate resistant starch (RS) when compared with other highly abundant species of amylolytic bacteria found in the human colon and have presented evidence that this bacterium provides an example of a keystone species within the microbial community with respect to RS fermentation. The concept of keystone species can be equally relevant to other activities, e.g., those involved in stabilizing the community.

Clement K.D.,Aberdeen Group
The Cochrane database of systematic reviews | Year: 2013

Urodynamic tests are used to investigate people who have urinary incontinence or other urinary symptoms in order to make a definitive, objective diagnosis. The aim is to help select the treatment most likely to be successful. The investigations are invasive and time consuming. The objective of this review was to determine if treatment according to a urodynamic-based diagnosis, compared to treatment based on history and examination, led to more effective clinical care of people with urinary incontinence and better clinical outcomes.The intention was to test the following hypotheses in predefined subgroups of people with incontinence:(i) urodynamic investigations improve the clinical outcomes;(ii) urodynamic investigations alter clinical decision making;(iii) one type of urodynamic test is better than another in improving the outcomes of management of incontinence or influencing clinical decisions, or both. We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE In-Process, handsearching of journals and conference proceedings (searched 19 February 2013), and the reference lists of relevant articles. Randomised and quasi-randomised trials comparing clinical outcomes in groups of people who were and were not investigated using urodynamics, or comparing one type of urodynamic test against another were included. Trials were excluded if they did not report clinical outcomes. Two review authors independently assessed trial quality and extracted data. Eight trials involving around 1100 people were included but data were only available for 1036 women in seven trials, of whom 526 received urodynamics. There was some evidence of risk of bias. The four deaths and 12 dropouts in the control arm of one trial were unexplained.There was significant evidence that the tests did change clinical decision making. Women in the urodynamic arms of three trials were more likely to have their management changed (proportion with change in management compared with the control arm 17% versus 3%, risk ratio (RR) 5.07, 95% CI 1.87 to 13.74), although there was statistical heterogeneity. There was evidence from two trials that women treated after urodynamic investigations were more likely to receive drugs (RR 2.09, 95% CI 1.32 to 3.31). On the other hand, in five trials women undergoing treatment following urodynamic investigation were not more likely to undergo surgery (RR 0.99, 95% CI 0.88 to 1.12).There was no statistically significant difference however in the number of women with urinary incontinence if they received treatment guided by urodynamics (37%) compared with those whose treatment was based on history and clinical findings alone (36%) (for example, RR for the number with incontinence after the first year 1.02, 95% CI 0.86 to 1.21). It was calculated that the number of women needed to treat was 100 women (95% CI 86 to 114 women) undergoing urodynamics to prevent one extra individual being incontinent at one year.One trial reported adverse effects and no significant difference was found (RR 1.10, 95% CI 0.81 to 1.50). While urodynamic tests did change clinical decision making, there was some evidence that this did not result in better outcomes in terms of a difference in urinary incontinence rates after treatment. There was no evidence about their use in men, children, or people with neurological diseases. Larger definitive trials are needed in which people are randomly allocated to management according to urodynamic findings or to management based on history and clinical examination to determine if performance of urodynamics results in higher continence rates after treatment.

Dambuza I.M.,Aberdeen Group | Brown G.D.,Aberdeen Group
Current Opinion in Immunology | Year: 2015

C-type lectin receptors (CLRs) comprise a large superfamily of proteins, which recognise a diverse range of ligands, and are defined by the presence of at least one C-type lectin-like domain (CTLD). Of particular interest are the single extracellular CTLD-containing receptors of the 'Dectin-1' and 'Dectin-2' clusters, which associate with signalling adaptors or possess integral intracellular signalling domains. These CLRs have traditionally been associated with the recognition of fungi, but recent discoveries have revealed diverse and unexpected functions. In this review, we describe their newly identified roles in anti-microbial host defence, homeostasis, autoimmunity, allergy and their functions in the recognition and response to dead and cancerous cells. © 2014 The Authors.

Brown G.D.,Aberdeen Group | Netea M.G.,Radboud University Nijmegen
Cell Host and Microbe | Year: 2012

The last decade has brought significant advances in our understanding of antifungal immunity, which offer hope for the development of novel immunotherapeutics. In this commentary, we provide a snapshot of the protective innate and adaptive components of antifungal immunity and highlight several recent topics of interest, placing in context the three associated reviews in this issue of Cell Host & Microbe. © 2012 Elsevier Inc.

Odds F.C.,Aberdeen Group
Future Microbiology | Year: 2010

Candida albicans, a diploid yeast commensal and opportunist pathogen, has evolved unusual mechanisms for maintenance of genetic diversity in the absence of a complete sexual cycle. These include chromosomal polymorphisms, mitotic recombination events, and gains and losses of heterozygosity, superimposed on a fundamentally clonal mode of reproduction. Molecular typing of C. albicans strains shows geographical evolutionary associations but these have become partially blurred, probably as a result of extensive human travel. Individual patients usually carry a single C. albicans strain type, but this may undergo microvariation leading to detection of mixtures of closely related types. Associations have been found between dade 1, the most common multilocus sequence typing cluster of related C. albicans strains, and resistance to flucytosine and terbinafine. There are also dade-related associations with lengths of tandem repeats in some cell-surface proteins, but not with virulence or type of infection. Copyright © 2010 Future Medicine Ltd.

Hall R.A.,Aberdeen Group | Gow N.A.R.,Aberdeen Group
Molecular Microbiology | Year: 2013

Summary: The fungal cell wall is a dynamic organelle required for cell shape, protection against the environment and, in pathogenic species, recognition by the innate immune system. The outer layer of the cell wall is comprised of glycosylated mannoproteins with the majority of these post-translational modifications being the addition of O- and N-linked mannosides. These polysaccharides are exposed on the outer surface of the fungal cell wall and are, therefore, the first point of contact between the fungus and the host immune system. This review focuses on O- and N-linked mannan biosynthesis in the fungal pathogen Candida albicans and highlights new insights gained from the characterization of mannosylation mutants into the role of these cell wall components in host-fungus interactions. In addition, we discuss the use of fungal mannan as a diagnostic marker of fungal disease. © 2013 The Authors.

Drummond R.A.,Aberdeen Group | Brown G.D.,Aberdeen Group
Current Opinion in Microbiology | Year: 2011

Dectin-1 is an innate immune pattern recognition receptor (PRR) that, through its ability to bind β-glucans, is involved in the recognition of several pathogenic fungi. Dectin-1 can stimulate a variety of cellular responses via the Syk/CARD9 signalling pathway, including phagocytosis, cytokine production and the respiratory burst. Several advances in our understanding of Dectin-1 immunobiology have been made in recent years, including characterisation of additional signalling pathways and demonstration of its ability to directly induce the development of adaptive immunity. However, the physiological role of many of the functions of this receptor is still unclear. This review aims to provide an update on Dectin-1 and its role within antifungal immune responses, focussing on progress made in the last two years. © 2011 Elsevier Ltd.

Brown G.D.,Aberdeen Group
Cell Host and Microbe | Year: 2010

Research into the interaction of fungi with the host has provided significant contributions to mammalian immunology. Here, I briefly review the most notable of these contributions, starting from the time of Metchnikoff, and highlight their impact on our understanding of immunity. © 2010 Elsevier Inc. All rights reserved.

Loading Aberdeen Group collaborators
Loading Aberdeen Group collaborators